Published: 6 June 2024


Quarterly summary of recent safety communications

Published: 6 June 2024
Prescriber Update 45(2): 36
June 2024

The table below is a summary of recent safety communications for healthcare professionals and consumers. Click on a specific topic to go to the communication.

Date Communication Topic
17/05/2024 Dear Healthcare Professional Letter Phenergan (promethazine): Restriction of oral formulation use in children less than 6 years of age (PDF, 4 pages, 88KB)
13/05/2024 Alert Promethazine (oral): Do not use in children under 6 years of age due to the risk of psychiatric and central nervous system side effects
02/05/2024 Dear Healthcare Professional Letter Paracetamol Kabi – shortage of 1000mg/100mL solution for injection vial and temporary supply of UK-labelled product (PDF, 2 pages, 115 KB)
24/04/2024 Dear Healthcare Professional Letter Oramorph – Supply of provisionally approved Oramorph 10mg/5mL to address supply shortage of morphine hydrochloride oral solution (PDF, 1 page, 242 KB)
08/04/2024 Alert Do not use NaturaCoco Moisturising Cream or Dok Apo Moisturiser Soothing Cream
08/04/2024 Monitoring M² Logo Calcium channel blockers and the possible risk of new-onset eczema
05/03/2024 Dear Healthcare Professional Letter Dexmedetomidine Viatris 200mcg/2mL concentrate for infusion – labelling exemption to allow supply of Dexmedetomidine Mylan from Australia (PDF, 1 page, 204 KB)
05/03/2024 Dear Healthcare Professional Letter Rocuronium bromide (Hameln) – supply of Croatian/Slovenian-labelled Rocuronium bromide (Hameln) solution for injection 10mg/mL (PDF, 3 pages, 427 KB)
February 2024 Dear Healthcare Professional Letter Coversyl – Changes to 4mg tablet appearance and changes to packaging (PDF, 4 pages, 457 KB)
Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /